Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial
Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial

MENLO PARK, CA and HELSINKI, FINLAND, Oct 1, 2021 – (ACN Newswire via SEAPRWire.com) – Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (“Apollomics”), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that... » read more

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

FOSTER CITY, Calif. and HANGZHOU, China and MENLO PARK, CA, Feb 10, 2021 – (ACN Newswire) – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and Edison Oncology Holding Corp., today announced that Apollomics has been granted worldwide rights, excluding China, Hong Kong and Taiwan,... » read more